ArticleSignal transduction and targeted therapy
Neuroretinal hypoxic signaling in a new preclinical murine model for proliferative diabetic retinopathy.
Article in Signal transduction and targeted therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Microglial polarization in retinal neovascularization: Friend or foe?Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
- Article
- Efficacy of Ophthalmic Viscosurgical Device-Assisted Vitrectomy for Membrane Removal in Patients With Complex Proliferative Diabetic Retinopathy.Journal of ophthalmology · 2026Article
- Novel Therapeutic Approaches for Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration.Vision (Basel, Switzerland) · 2025Review
- Retinal ischemic diseases and promising therapeutic molecular targets.Histology and histopathology · 2025Review
- Multi-targeted pharmacological actions and nanodelivery strategies of Garcinia cambogia: from molecular mechanisms to disease treatment.Frontiers in chemistry · 2025Review
- Engineered mesenchymal stem cell-derived small extracellular vesicles for diabetic retinopathy therapy through HIF-1α/EZH2/PGC-1α pathway.Bioactive materials · 2024Article
- Protective effects of piperine on the retina of mice with streptozotocin-induced diabetes by suppressing HIF-1/VEGFA pathway and promoting PEDF expression.International journal of ophthalmology · 2021Article
- Clinical Pathological Features and Current Animal Models of Type 3 Macular Neovascularization.Frontiers in neuroscience · 2021Review
- Uncovering the protective mechanism of Taohong Siwu decoction against diabetic retinopathy via HIF-1 signaling pathway based on network analysis and experimental validation.BMC complementary medicine and therapies · 2020Article
- CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials.Human mutation · 2019Article
- Hypoxic drive caused type 3 neovascularization in a preclinical model of exudative age-related macular degeneration.Human molecular genetics · 2019Article
- Extracellular superoxide dismutase (SOD3) regulates oxidative stress at the vitreoretinal interface.Free radical biology & medicine · 2018Article
- Attenuation of Retinal Vascular Development in Neonatal Mice Subjected to Hypoxic-Ischemic Encephalopathy.Scientific reports · 2018Article
- Effective improvement of the neuroprotective activity after spinal cord injury by synergistic effect of glucocorticoid with biodegradable amphipathic nanomicelles.Drug delivery · 2017Article
- The Promotion of Erythropoiesis via the Regulation of Reactive Oxygen Species by Lactic Acid.Scientific reports · 2017Article
- Retinal and choroidal angiogenesis: a review of new targets.International journal of retina and vitreous · 2017Review
- Zonisamide-loaded triblock copolymer nanomicelles as a novel drug delivery system for the treatment of acute spinal cord injury.International journal of nanomedicine · 2017Article
- Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies.International journal of nanomedicineArticle
- miR-142-5p regulates the progression of diabetic retinopathy by targeting IGF1.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
Diabetic retinopathy (DR) affects approximately one-third of diabetic patients and, if left untreated, progresses to proliferative DR (PDR) with associated vitreous hemorrhage, retinal detachment, iris neovascularization, glaucoma and irreversible blindness. In vitreous samples of human patients with PDR, we found elevated levels of hypoxia inducible factor 1 alpha (HIF1α). HIFs are transcription factors that promote hypoxia adaptation and have important functional roles in a wide range of ischemic and inflammatory diseases. To recreate the human PDR phenotype for a preclinical animal model, we generated a mouse with neuroretinal-specific loss of the von Hippel Lindau tumor suppressor protein, a protein that targets HIF1α for ubiquitination. We found that the neuroretinal cells in these mice overexpressed HIF1α and developed severe, irreversible ischemic retinopathy that has features of human PDR. Rapid progression of retinopathy in these mutant mice should facilitate the evaluation of therapeutic agents for ischemic and inflammatory blinding disorders. In addition, this model system can be used to manipulate the modulation of the hypoxia signaling pathways, for the treatment of non-ocular ischemic and inflammatory disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.